Cited by 127Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and TreatmentsChromatin Remodeling and Cancer

The DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index, and 1 are not checked yet.

Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group

Open access

Roberts, Ryan D., Lizardo, Michael M., Reed, Damon R., Hingorani, Pooja, Glover, Jason, Allen‐Rhoades, Wendy, Fan, Timothy, Khanna, Chand, Sweet‐Cordero, E. Alejandro, Cash, Thomas, Bishop, Michael W., Hegde, Meenakshi, Sertil, Aparna R., Koelsche, Christian, Mirabello, Lisa, Malkin, David, Sorensen, Poul H., Meltzer, Paul S., Janeway, Katherine A., Gorlick, Richard, Crompton, Brian D.·2019·Cancer

DOI 10.1002/cncr.32351PMC PMC6948723

Open this paper in CoChat — free account

Abstract

Patients who are diagnosed with osteosarcoma (OS) today receive the same therapy that patients have received over the last 4 decades. Extensive efforts to identify more effective or less toxic regimens have proved disappointing. As we enter a postgenomic era in which we now recognize OS not as a cancer of mutations but as one defined by p53 loss, chromosomal complexity, copy number alteration, and profound heterogeneity, emerging threads of discovery leave many hopeful that an improving understanding of biology will drive discoveries that improve clinical care. Under the organization of the Bone Tumor Biology Committee of the Children's Oncology Group, a team of clinicians and scientists sought to define the state of the science and to identify questions that, if answered, have the greatest potential to drive fundamental clinical advances. Having discussed these questions in a series of meetings, each led by invited experts, we distilled these conversations into a series of seven Provocative Questions. These include questions about the molecular events that trigger oncogenesis, the genomic and epigenomic drivers of disease, the biology of lung metastasis, research models that best predict clinical outcomes, and processes for translating findings into clinical trials. Here, we briefly present each Provocative Question, review the current scientific evidence, note the immediate opportunities, and speculate on the impact that answered questions might have on the field. We do so with an intent to provide a framework around which investigators can build programs and collaborations to tackle the hardest problems and to establish research priorities for those developing policies and providing funding.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/cncr.32351

Cites

93 of 94 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
The landscape of genomic alterations across childhood cancers
ICGC PedBrain-Seq Project, Gröbner, S. N., ICGC MMML-Seq Project, Worst, B. C., Weischenfeldt, J., Buchhalter, I., Kleinheinz, K., Rudneva, V. A., Johann, P. D., Balasubramanian, G. P., et al. (2018) · Nature · doi:10.1038/nature25480 · Cited by 1,572
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452 · cited 1×
“study, only 1 of the 22 patients with OS had an objective response to single agent pembrolizumab.(81) In the pediatric trial of nivolumab alone or in combination with ip-”
BackgroundSelf-citation
Oxidative stress inhibits distant metastasis by human melanoma cells
Piskounova, E., Agathocleous, M., Murphy, M. M., Hu, Z., Huddlestun, S. E., Zhao, Z., Leitch, A. M., Johnson, T. M., DeBerardinis, R. J., & Morrison, S. J. (2015) · Nature · doi:10.1038/nature15726 · Cited by 1,269
Metastasis: Quantitative Analysis of Distribution and Fate of Tumor Emboli Labeled With 125I-5-Iodo-2′ -deoxyuridine 2 3
Fidler, I. J. (1970) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/45.4.773 · Cited by 1,025
Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours
Ma, X., Liu, Y., Liu, Y., Alexandrov, L. B., Edmonson, M. N., Gawad, C., Zhou, X., Li, Y., Rusch, M. C., Easton, J., et al. (2018) · Nature · doi:10.1038/nature25795 · Cited by 901
Self-citation
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 900
Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency
Bouffet, E., Larouche, V., Campbell, B. B., Merico, D., de Borja, R., Aronson, M., Durno, C., Krueger, J., Cabric, V., Ramaswamy, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6552 · Cited by 857
Self-citation
Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers
Bougeard, G., Renaux-Petel, M., Flaman, J.-M., Charbonnier, C., Fermey, P., Belotti, M., Gauthier-Villars, M., Stoppa-Lyonnet, D., Consolino, E., Brugières, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5728 · Cited by 760
Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
Chen, X., Bahrami, A., Pappo, A., Easton, J., Dalton, J., Hedlund, E., Ellison, D., Shurtleff, S., Wu, G., Wei, L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.003 · Cited by 752
The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas.
McCarthy, E. F. (2006) · Europe PMC (PubMed Central) · Cited by 747
The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis
Khanna, C., Wan, X., Bose, S., Cassaday, R., Olomu, O., Mendoza, A., Yeung, C., Gorlick, R., Hewitt, S. M., & Helman, L. J. (2004) · Nature Medicine · doi:10.1038/nm982 · Cited by 705
Self-citation
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
Marina, N. M., Smeland, S., Bielack, S. S., Bernstein, M., Jovic, G., Krailo, M. D., Hook, J. M., Arndt, C., van den Berg, H., Brennan, B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30214-5 · Cited by 551
Self-citation
Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li‐Fraumeni syndrome cohort
Mai, P. L., Best, A. F., Peters, J. A., DeCastro, R. M., Khincha, P. P., Loud, J. T., Bremer, R. C., Rosenberg, P. S., & Savage, S. A. (2016) · Cancer · doi:10.1002/cncr.30248 · Cited by 487
Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma
Zhukova, N., Ramaswamy, V., Remke, M., Pfaff, E., Shih, D. J. H., Martin, D. C., Castelo‐Branco, P., Baskin, B., Ray, P. N., Bouffet, É., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5052 · Cited by 482
Self-citation
Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma
Perry, J. A., Kiezun, A., Tonzi, P., Van Allen, E. M., Carter, S. L., Baca, S. C., Cowley, G. S., Bhatt, A. S., Rheinbay, E., Pedamallu, C. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419260111 · Cited by 481
Self-citation
Germline and somatic genetics of osteosarcoma — connecting aetiology, biology and therapy
Gianferante, D. M., Mirabello, L. J., & Savage, S. A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.16 · Cited by 477
Self-citation
Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response.
Winkler, K., Beron, G., Delling, G., Heise, U., Kabisch, H., Purfürst, C., Berger, J., Ritter, J., Jürgens, H., & Gerein, V. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.2.329 · Cited by 457
Genome-Informed Targeted Therapy for Osteosarcoma
Sayles, L. C., Breese, M. R., Koehne, A. L., Leung, S. G., Lee, A. G., Liu, H.-Y., Spillinger, A., Shah, A. T., Tanasa, B., Straessler, K., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1152 · Cited by 452
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
Bielack, S. S., Smeland, S., Whelan, J. S., Marina, N., Jovic, G., Hook, J. M., Krailo, M. D., Gebhardt, M., Pápai, Z., Meyer, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0734 · Cited by 422
Self-citation
Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency.
Cameron, M. D., Schmidt, E. E., Kerkvliet, N. I., Nadkarni, K. V., Morris, V. L., Groom, A. C., Chambers, A. F., & MacDonald, I. C. (2000) · PubMed · Cited by 400
Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency
Kovac, M., Blattmann, C., Ribi, S., Smida, J., Mueller, N. S., Engert, F., Castro-Giner, F., Weischenfeldt, J., Kovacova, M., Krieg, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms9940 · Cited by 353
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment
Whelan, J. S., Bielack, S., Marina, N. M., Smeland, S., Jovic, G., Hook, J., Krailo, M., Anninga, J., Butterfaß‐Bahloul, T., Böhling, T., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu526 · Cited by 334
Self-citation
Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression
Paoloni, M., Davis, S., Lana, S., Withrow, S., Sangiorgi, L., Picci, P., Hewitt, S., Triche, T., Meltzer, P., & Khanna, C. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-625 · Cited by 291
Self-citation
Li-Fraumeni syndrome: cancer risk assessment and clinical management
McBride, K. A., Ballinger, M. L., Killick, E., Kirk, J., Tattersall, M. H. N., Eeles, R. A., Thomas, D. M., & Mitchell, G. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.41 · Cited by 286
Orthotopic patient-derived xenografts of paediatric solid tumours
Stewart, E., Federico, S. M., Chen, X., Shelat, A. A., Bradley, C., Gordon, B., Karlstrom, A., Twarog, N. R., Clay, M. R., Bahrami, A., et al. (2017) · Nature · doi:10.1038/nature23647 · Cited by 286
Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
Koirala, P., Roth, M. E., Gill, J., Piperdi, S., Chinai, J. M., Geller, D. S., Hoang, B. H., Park, A., Fremed, M. A., Zang, X., et al. (2016) · Scientific Reports · doi:10.1038/srep30093 · Cited by 267
Self-citation
Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma
Behjati, S., Tarpey, P. S., Haase, K., Ye, H., Young, M. D., Alexandrov, L. B., Farndon, S. J., Collord, G., Wedge, D. C., Martincorena, I., et al. (2017) · Nature Communications · doi:10.1038/ncomms15936 · Cited by 261
Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes
Lauvrak, S. U., Munthe, E., Kresse, S. H., Stratford, E. W., Namløs, H. M., Meza‐Zepeda, L. A., & Myklebost, O. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.549 · Cited by 252
Canine Osteosarcoma: A Naturally Occurring Disease to Inform Pediatric Oncology
Fenger, J. M., London, C. A., & Kisseberth, W. C. (2014) · ILAR Journal · doi:10.1093/ilar/ilu009 · Cited by 248
Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype
Almog, N., Ma, L., Raychowdhury, R., Schwager, C., Erber, R., Short, S., Hlatky, L., Vajkoczy, P., Huber, P. E., Folkman, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2590 · Cited by 240
The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma
Heymann, M.-F., Lézot, F., & Heymann, D. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.10.011 · Cited by 233
Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases
Aljubran, A. H., Griffin, A., Pintilie, M., & Blackstein, M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn731 · Cited by 230
Children's Oncology Group's 2013 blueprint for research: Bone tumors
Gorlick, R., Janeway, K., Lessnick, S., Randall, R. L., Marina, N., & on behalf of the COG Bone Tumor Committee (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24429 · Cited by 226
Self-citation
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
Lussier, D. M., Johnson, J. L., Hingorani, P., & Blattman, J. N. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0067-z · Cited by 206
Self-citation
Genome-wide association study identifies two susceptibility loci for osteosarcoma
Savage, S. A., Mirabello, L. J., Wang, Z., Gastier, J. M., Gorlick, R. G., Khanna, C., Flanagan, A. M., Tirabosco, R., Andrulis, I. L., Wunder, J. S., et al. (2013) · Nature Genetics · doi:10.1038/ng.2645 · Cited by 200
Self-citation
Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions
Lussier, D. M., O’Neill, L., Nieves, L. M., McAfee, M. S., Holechek, S. A., Collins, A. W., Dickman, P., Jacobsen, J., Hingorani, P., & Blattman, J. N. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000065 · Cited by 197
Self-citation
Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward
Lagmay, J. P., Krailo, M. D., Dang, H., Kim, A., Hawkins, D. S., Beaty, O., Widemann, B. C., Zwerdling, T., Bomgaars, L., Langevin, A.-M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5381 · Cited by 190
Self-citation
Alterations of thep53, Rb andMDM2 genes in osteosarcoms
Miller, C. W., Aslo, A., Won, A., Tan, M., Lampkin, B. C., & Koefflar, H. P. (1996) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01213553 · Cited by 188
Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression
Baglio, S. R., Lagerweij, T., Pérez-Lanzón, M., Ho, X. D., Léveillé, N., Melo, S. A., Cleton-Jansen, A.-M., Jordanova, E. S., Roncuzzi, L., Greco, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2726 · Cited by 187
The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation
Tsai, Y. C., Mendoza, A., Mariano, J. M., Zhou, M., Kostova, Z., Chen, B., Veenstra, T., Hewitt, S. M., Helman, L. J., Khanna, C., et al. (2007) · Nature Medicine · doi:10.1038/nm1686 · Cited by 186
Self-citation
Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma
Khanna, C., Fan, T. M., Gorlick, R., Helman, L. J., Kleinerman, E. S., Adamson, P. C., Houghton, P. J., Tap, W. D., Welch, D. R., Steeg, P. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2574 · Cited by 178
Self-citation
Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma
Mason, N. J., Gnanandarajah, J. S., Engiles, J. B., Gray, F., Laughlin, D., Gaurnier-Hausser, A., Wallecha, A., Huebner, M., & Paterson, Y. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0088 · Cited by 178 · cited 1×
“The spontaneous nature of this disease, the shared environmental context, the shorter natural history of the dog disease, and the increasing capacity of collaborative clinical trials groups within the veterinary community make this a primary early target of comparative oncology efforts.(42,43) The canine patient may b…”
Background
A biobank of patient-derived pediatric brain tumor models
Brabetz, S., Leary, S. E. S., Gröbner, S. N., Nakamoto, M. W., Seker‐Cin, H., Girard, E. J., Cole, B., Strand, A. D., Bloom, K., Hovestadt, V., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0207-3 · Cited by 178
SHH mutation is associated with solitary median maxillary central incisor: A study of 13 patients and review of the literature
Nanni, L., Ming, J. E., Du, Y., Hall, R. K., Aldred, M. J., Bankier, A., & Muenke, M. (2001) · American Journal of Medical Genetics · doi:10.1002/1096-8628(20010722)102:1 · Cited by 174
A permanent window for the murine lung enables high-resolution imaging of cancer metastasis
Entenberg, D. R., Voiculescu, S. E., Guo, P., Borriello, L., Wang, Y., Karagiannis, G. S., Jones, J. G., Baccay, F., Oktay, M. H., & Condeelis, J. S. (2017) · Nature Methods · doi:10.1038/nmeth.4511 · Cited by 174
Positively selected enhancer elements endow osteosarcoma cells with metastatic competence
Morrow, J. J., Bayles, I., Funnell, A. P. W., Miller, T. E., Saiakhova, A., Lizardo, M. M., Bartels, C. F., Kapteijn, M. Y., Hung, S., Mendoza, A., et al. (2018) · Nature Medicine · doi:10.1038/nm.4475 · Cited by 161
Self-citation
Germline TP53 Variants and Susceptibility to Osteosarcoma
Mirabello, L., Yeager, M., Mai, P. L., Gastier-Foster, J. M., Gorlick, R., Khanna, C., Patiño-Garcia, A., Sierrasesúmaga, L., Lecanda, F., Andrulis, I. L., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv101 · Cited by 155
Self-citation
Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma
Man, T., Lu, X.-Y., Jaeweon, K., Perlaky, L., Harris, C. P., Shah, S. K., Ladanyi, M., Gorlick, R. G., Lau, C. C., & Rao, P. H. (2004) · BMC Cancer · doi:10.1186/1471-2407-4-45 · Cited by 147
Self-citation
Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin.
Kurzman, I. D., MacEwen, E. G., ROSENTHAL, R. C., Fox, L. E., Keller, E. T., Helfand, S. C., Vail, D. M., Dubielzig, R. R., Madewell, B. R., & Rodriguez, C. O. (1995) · PubMed · Cited by 142
NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma
Zhao, S., Kurenbekova, L., Gao, Y., Roos, A., Creighton, C. J., Rao, P., Hicks, J., Man, T.-K., Lau, C., Brown, A. M. C., et al. (2015) · Oncogene · doi:10.1038/onc.2014.429 · Cited by 139
Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers
Hettmer, S., Archer, N. M., Somers, G. R., Novokmet, A., Wagers, A. J., Diller, L., Galindo, C. R., Teot, L. A., & Malkin, D. M. (2013) · Cancer · doi:10.1002/cncr.28507 · Cited by 135
Self-citation
Molecular Characterization of the Pediatric Preclinical Testing Panel
Neale, G. A. M., Su, X., Morton, C. L., Phelps, D. A., Gorlick, R. G., Lock, R. B., Reynolds, C. P., Maris, J. M., Friedman, H. S., Dome, J. S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5090 · Cited by 117
Self-citation
Characterization of the metastatic phenotype of a panel of established osteosarcoma cells
Ren, L., Mendoza, A., Zhu, J., Briggs, J., Halsey, C., Hong, E. S., Burkett, S. S., Morrow, J. J., Lizardo, M. M., Osborne, T. S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5177 · Cited by 116
Self-citation
Bayesian methods for the design and interpretation of clinical trials in very rare diseases
Hampson, L. V., Whitehead, J., Eleftheriou, D., & Brogan, P. A. (2014) · Statistics in Medicine · doi:10.1002/sim.6225 · Cited by 103
Modeling metastasis biology and therapy in real time in the mouse lung
Mendoza, A., Hong, S.-H., Osborne, T., Khan, M. A., Campbell, K., Briggs, J., Eleswarapu, A., Buquo, L., Ren, L., Hewitt, S. M., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40252 · Cited by 92
Self-citation
Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors
Ratti, C., Botti, L., Cancila, V., Galvan, S., Torselli, I., Garofalo, C., Manara, M. C., Bongiovanni, L., Valenti, C. F., Burocchi, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3186 · Cited by 89
IGF2 Preserves Osteosarcoma Cell Survival by Creating an Autophagic State of Dormancy That Protects Cells against Chemotherapeutic Stress
Shimizu, T., Sugihara, E., Yamaguchi‐Iwai, S., Tamaki, S., Koyama, Y., Kamel, W., Ueki, A., Ishikawa, T., Chiyoda, T., Osuka, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0914 · Cited by 87
Identification of Dormancy-Associated MicroRNAs for the Design of Osteosarcoma-Targeted Dendritic Polyglycerol Nanopolyplexes
Tiram, G., Segal, E., Krivitsky, A., Shreberk‐Hassidim, R., Ferber, S., Ofek, P., Udagawa, T., Edry, L., Shomron, N., Roniger, M., et al. (2016) · ACS Nano · doi:10.1021/acsnano.5b06189 · Cited by 87
IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis
Gross, A. C., Cam, H., Phelps, D. A., Saraf, A. J., Bid, H. K., Cam, M., London, C. A., Winget, S. A., Arnold, M. A., Brandolini, L., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99791 · Cited by 82
Self-citation
A genome-wide approach to comparative oncology: high-resolution oligonucleotide aCGH of canine and human osteosarcoma pinpoints shared microaberrations
Angstadt, A. Y., Thayanithy, V., Subramanian, S., Modiano, J. F., & Breen, M. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2012.09.005 · Cited by 81
The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities
Stewart, E. A., Federico, S. M., Karlström, Å., Shelat, A. A., Sablauer, A., Pappo, A. S., & Dyer, M. A. (2015) · Developmental Biology · doi:10.1016/j.ydbio.2015.03.001 · Cited by 79
Metastatic inefficiency in mice bearing B16 melanomas
Weiss, L., Mayhew, E. G., Rapp, D., & Holmes, J. C. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.6 · Cited by 78
TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome
Ribi, S., Baumhoer, D., Lee, K., Edison, Teo, A. S. M., Madan, B., Zhang, K., Kohlmann, W. K., Yao, F., Lee, W. H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3115 · Cited by 75
Animal Models in Osteosarcoma
Guijarro, M. V., Ghivizzani, S. C., & Gibbs, C. P. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00189 · Cited by 73
Arrest of B16 Melanoma Cells in the Mouse Pulmonary Microcirculation Induces Endothelial Nitric Oxide Synthase-Dependent Nitric Oxide Release that Is Cytotoxic to the Tumor Cells
Qiu, H., Orr, F. W., Jensen, D., Wang, H. H., McIntosh, A. R., Hasinoff, B. B., Nance, D. M., Pylypas, S. P., Qi, K., Song, C. H., et al. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63835-7 · Cited by 73
Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma
Gupte, A., Baker, E. K., Wan, S.-S., Stewart, E. A., Loh, A. H. P., Shelat, A. A., Gould, C. M., Chalk, A. M., Taylor, S., Lackovic, K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3026 · Cited by 70
Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis
Murphy, B., Yin, H., Maris, J. M., Kolb, E. A., Gorlick, R., Reynolds, C. P., Kang, M. H., Keir, S. T., Kurmasheva, R. T., Dvorchik, I., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0122 · Cited by 69
Self-citation
Children's and Their Parents' Views on Facing Research Risks for the Benefit of Others
Wendler, D. S., & Jenkins, T. L. (2008) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpediatrics.2007.3 · Cited by 66
Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma
Guenther, L. M., Rowe, R. G., Acharya, P. T., Swenson, D. W., Meyer, S. C., Clinton, C. M., Guo, D., Sridharan, M., London, W. B., Grier, H. E., et al. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26896 · Cited by 66
Self-citation
Fas-Negative Osteosarcoma Tumor Cells Are Selected during Metastasis to the Lungs: The Role of the Fas Pathway in the Metastatic Process of Osteosarcoma
Koshkina, N. V., Khanna, C., Mendoza, A., Guan, H., DeLauter, L., & Kleinerman, E. S. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0007 · Cited by 64
Self-citation
Increased CTLA-4+ T cells and an increased ratio of monocytes with loss of class II (CD14+ HLA-DRlo/neg) found in aggressive pediatric sarcoma patients
Hingorani, P., Maas, M. L., Gustafson, M. P., Dickman, P. S., Adams, R. H., Watanabe, M., Eshun, F., Williams, J., Seidel, M. J., & Dietz, A. B. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0082-0 · Cited by 62
Self-citation
Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 proteinPreprint
Pourebrahim, R., Zhang, Y., Liu, B., Gao, R., Xiong, S., Lin, P. P., McArthur, M. J., Ostrowski, M. C., & Lozano, G. (2017) · Genes & Development · doi:10.1101/gad.304972.117 · Cited by 62
TP53 Mutations and Survival in Osteosarcoma Patients: A Meta-Analysis of Published Data
Chen, Z., Guo, J., Zhang, K., & Guo, Y. (2016) · Disease Markers · doi:10.1155/2016/4639575 · Cited by 59
Comparative Aspects of Osteosarcoma Pathogenesis in Humans and Dogs
Fan, T. M., & Khanna, C. (2015) · Veterinary Sciences · doi:10.3390/vetsci2030210 · Cited by 57
Self-citation
ΔNp63 Promotes Pediatric Neuroblastoma and Osteosarcoma by Regulating Tumor Angiogenesis
Bid, H. K., Roberts, R. D., Cam, M., Audino, A. N., Kurmasheva, R. T., Lin, J., Houghton, P. J., & Çam, H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0894 · Cited by 57
Self-citation
Radiation enhanced the local and distant anti-tumor efficacy in dual immune checkpoint blockade therapy in osteosarcoma
Takahashi, Y., Yasui, T., Tamari, K., Minami, K., Otani, K., Isohashi, F., Seo, Y., Kambe, R., Koizumi, M., & Ogawa, K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189697 · Cited by 52
Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop
Hingorani, P., Janeway, K. A., Crompton, B. D., Kadoch, C., Mackall, C. L., Khan, J. I., Shern, J. F., Schiffman, J. D., Mirabello, L. J., Savage, S. A., et al. (2016) · Cancer Genetics · doi:10.1016/j.cancergen.2016.03.004 · Cited by 51
Self-citation
Upregulation of Glucose-Regulated Protein 78 in Metastatic Cancer Cells Is Necessary for Lung Metastasis Progression
Lizardo, M. M., Morrow, J. J., Miller, T. E., Hong, E. S., Ren, L., Mendoza, A., Halsey, C. H., Scacheri, P. C., Helman, L. J., & Khanna, C. (2016) · Neoplasia · doi:10.1016/j.neo.2016.09.001 · Cited by 50
Self-citation
Humanized mice: novel model for studying mechanisms of human immune-based therapies
Gonzalez, L. E., Štrbo, N., & Podack, E. R. (2013) · Immunologic Research · doi:10.1007/s12026-013-8471-2 · Cited by 43
Osteosarcomagenesis: Modeling Cancer Initiation in the Mouse
Jones, K. B. (2011) · Sarcoma · doi:10.1155/2011/694136 · Cited by 40
Maximum benefit of chemotherapy for osteosarcoma achieved—what are the next steps?
Kleinerman, E. S. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30270-4 · Cited by 34
Genetically transforming human osteoblasts to sarcoma: development of an osteosarcoma model
Yang, Y., Yang, R. R., Roth, M. E., Piperdi, S., Zhang, W., Dorfman, H. D., Rao, P. H., Park, A., Tripathi, S., Freeman, C., et al. (2017) · Genes & Cancer · doi:10.18632/genesandcancer.133 · Cited by 32
Self-citation
A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group
Isakoff, M. S., Goldsby, R. E., Villaluna, D., Krailo, M., Hingorani, P., Collier, A. B., Morris, C. D., Kolb, E. A., Doski, J. J., Womer, R. B., et al. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27524 · Cited by 29
Self-citation
GRM4 gene polymorphism is associated with susceptibility and prognosis of osteosarcoma in a Chinese Han population
Jiang, C., Chen, H., Shao, L., & Dong, Y. (2014) · Medical Oncology · doi:10.1007/s12032-014-0050-4 · Cited by 24
Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
Lizardo, M. M., & Sorensen, P. H. (2018) · Journal of Visualized Experiments · doi:10.3791/56332 · Cited by 19
Self-citation
A Bayesian Gene-Based Genome-Wide Association Study Analysis of Osteosarcoma Trio Data Using a Hierarchically Structured Prior
Yang, Y. A., Basu, S., Mirabello, L. J., Spector, L. G., & Zhang, L. (2018) · Cancer Informatics · doi:10.1177/1176935118775103 · Cited by 19
Self-citation
Reasons for participation in optional pharmacokinetic studies in children with cancer: A Children's Oncology Group phase 1 consortium study
Berg, S. L., Winick, N., Ingle, A. M., Adamson, P. C., & Blaney, S. M. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22529 · Cited by 17
Rapid Protocol Enrollment in Osteosarcoma: A Report From the Children's Oncology Group
Isakoff, M. S., Goldsby, R. E., Villaluna, D., Krailo, M., Gorlick, R. G., Doski, J. J., Womer, R. B., & Janeway, K. A. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25754 · Cited by 14
Self-citation
Automated quantitative image analysis for ex vivo metastasis assays reveals differing lung composition requirements for metastasis suppression by KISS1
Young, E. D., Strom, K. B., Tsue, A. F., Usset, J. L., MacPherson, S., McGuire, J. T., & Welch, D. R. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9882-1 · Cited by 9
Characterization of cancer-associated missense mutations in MDM2
Chauhan, K. M., Ramakrishnan, G., Kollareddy, M., & Martinez, L. A. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1125986 · Cited by 8
Abstract B40: Autocrine and paracrine IL-6 and IL-8 drive osteosarcoma lung tropism and facilitate metastasis
Roberts, R. D., Gross, A. C., Bid, H. K., Phelps, D. A., Wedekind, M. F., & Houghton, P. J. (2016) · Cancer Research · doi:10.1158/1538-7445.pedca15-b40 · Cited by 4
Self-citation
Abstract LB-291: Environment or accident? A more stringent bound on environmental contributions to cancerogenesis
Bilke, S., & Meltzer, P. S. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-lb-291 · Cited by 2
Self-citation
Abstract 3500: NCI's Provocative Questions Initiative
Berny‐Lang, M. A., & Greenspan, E. J. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-3500 · Cited by 1

Flagged first, then by citations

Sorted by citations

Osteosarcoma
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Self-citation
Sarcoma treatment in the era of molecular medicine
Grünewald, T. G., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre‐Aranaz, F., Di Pompo, G., Distel, M., Dorado‐Garcia, H., Garcia‐Castro, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911131 · Cited by 319
Self-citation
Future Directions in the Treatment of Osteosarcoma
Smrke, A., Anderson, P. M., Gulia, A., Gennatas, S., Huang, P. H., & Jones, R. L. (2021) · Cells · doi:10.3390/cells10010172 · Cited by 230
A novel photothermally controlled multifunctional scaffold for clinical treatment of osteosarcoma and tissue regeneration
Ma, L., Feng, X., Liang, H., Wang, K., Song, Y., Tan, L., Wang, B., Luo, R., Liao, Z., Li, G., et al. (2020) · Materials Today · doi:10.1016/j.mattod.2019.12.005 · Cited by 211
Improving human cancer therapy through the evaluation of pet dogs
LeBlanc, A. K., & Mazcko, C. N. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0297-3 · Cited by 207

See all 127

Authors: Roberts, R. D., Lizardo, M. M., Reed, D. R., Hingorani, P., Glover, J., Allen‐Rhoades, W., Fan, T., Khanna, C., Sweet‐Cordero, E. A., Cash, T., Bishop, M. W., Hegde, M., Sertil, A. R., Koelsche, C., Mirabello, L., Malkin, D., Sorensen, P. H., Meltzer, P. S., Janeway, K. A., Gorlick, R., & Crompton, B. D.
Affiliations: Nationwide Children's Hospital (US)
BC Cancer Agency (CA)
Moffitt Cancer Center (US)
Phoenix Children's Hospital (US)
Randall Children's Hospital at Legacy Emanuel (US)
Baylor College of Medicine (US)
University of Illinois Urbana-Champaign (US)
Ethos Vet Health Woburn Massachusetts
Division of Hematology and Oncology, Department of Pediatrics University of California San Francisco San Francisco California
Emory University (US)
St. Jude Children's Research Hospital (US)
University of Arizona (US)
Heidelberg University (DE)
National Institutes of Health (US)
University of Toronto (CA)
Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
The University of Texas MD Anderson Cancer Center (US)
Broad Institute (US)
Corresponding author: Crompton, Brian D.
ORCID: Roberts, Ryan D.
Lizardo, Michael M.
Reed, Damon R.
Hingorani, Pooja
Glover, Jason
Allen‐Rhoades, Wendy
Fan, Timothy
Bishop, Michael W.
Hegde, Meenakshi
Koelsche, Christian
Mirabello, Lisa
Malkin, David
Sorensen, Poul H.
Meltzer, Paul S.
Janeway, Katherine A.
Gorlick, Richard
Crompton, Brian D.
Venue: Cancer
Publisher: Wiley
Published: 2019-07-29
Volume: 125
Issue: 20
Pages: 3514-3525
ISSN: 0008-543X (ISSN-L)
1097-0142
DOI: 10.1002/cncr.32351
PMC: PMC6948723
OpenAlex: W2966831493
Cited by: 127
References: 92
Citations by year: 2026: 7 · 2025: 13 · 2024: 15 · 2023: 18 · 2022: 29 · 2021: 24 · 2020: 19 · 2019: 2
FWCI: 3.12
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Cancer (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (U10CA180886, K08CA188073, K08CA201638)
Topics: Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: osteosarcoma, p53 deficiency, copy number alterations, tumor heterogeneity, carcinogenesis, epigenomics, lung metastasis, preclinical models, translational research, research priorities, Children's Oncology Group
MeSH terms: Child, Humans, Mutation, Osteosarcoma, Tumor Suppressor Protein p53, Genomics, Proteomics, Translational Research, Biomedical, Epigenomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks